ATTONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Attovia Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 2, 2026
$13.89+0.16 (+1.17%)
Close on Oct 19, 2026
- Market cap
- $58.86M
- P/E (TTM)
- –
- Dividend yield
- –
Attovia Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Attovia Therapeutics | Industry median |
|---|---|---|
| Market Cap | $62.91M | $166.30M |
| Enterprise Value | -$52.22M | $88.19M |
Balance sheet
| Measure | Attovia Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $115.13M | $61.43M |
| Net Cash (Debt) | $115.13M | $15.35M |
| Net Cash Per Share | $25.42 | $0.66 |
| Equity (Book Value) | -$145.46M | $49.09M |
| Book Value Per Share | -$32.12 | $1.37 |
| Tangible Book Value | -$145.46M | $23.52M |
| Working Capital | $105.79M | $76.81M |
Financial position
| Measure | Attovia Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 9.39 | 3.34 |
| Quick Ratio | 9.13 | 2.44 |
Shares
| Measure | Attovia Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 4,529,100 | 58,127,000 |
Scores
| Measure | Attovia Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 1.77 | -0.22 |
Calculated by StockData from Attovia Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.